VC activity in the biopharma modalities sector consolidated significantly in Q4 2024. Deal counts fell 12% year-over-year even as total deal value climbed 20% to $32.1 billion, according to PitchBook’s latest report on the space. This trend underscores a market shift toward fewer, high-value investments in mature, late-stage clinical assets. Looking ahead to 2025, robust M&A activity is expected to continue, particularly for companies with differentiated clinical-stage assets.
Read the full article: PitchBook Report: Biopharma Modalities VC Ecosystem Matures with Fewer, Larger Deals //
Source: https://pitchbook.com/news/reports/q4-2024-biopharma-modalities-vc-trends